A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : LF / Lassa fever

[Related PubMed/MEDLINE]
Total Number of Papers: 60
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   LF  (>> Co-occurring Abbreviation)
Long Form:   Lassa fever
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2019 Attenuated Replication of Lassa Virus Vaccine Candidate ML29 in STAT-1-/- Mice. IPs, LASV, MOPV
2019 Lassa virus diversity and feasibility for universal prophylactic vaccine. LASV, TPP, WHO
2018 Acute Abdomen in Pediatric Patients With Lassa Fever: Prevalence and Response to Nonoperative Management. AAbd
2018 Baseline mapping of Lassa fever virology, epidemiology and vaccine research and development. GPC, LASV, NP, VSV
2018 Current research for a vaccine against Lassa hemorrhagic fever virus. LASV
2018 Genetic characterization of Lassa virus strains isolated from 2012 to 2016 in southeastern Nigeria. LASV, RT-PCR
2018 Knowledge of Lassa fever and use of infection prevention and control facilities among health care workers during Lassa fever outbreak in Ondo State, Nigeria. HCs, HCWs, IPC, LGAs
2018 Lassa Fever 2016 Outbreak in Plateau State, Nigeria-The Changing Epidemiology and Clinical Presentation. ---
2018 Lassa fever outbreak in adolescents in North Central Nigeria: report of cases. RT-PCR
10  2018 Lassa fever-induced sensorineural hearing loss: A neglected public health and social burden. LASV, SNHL
11  2018 Lessons Learnt from Epidemiological Investigation of Lassa Fever Outbreak in a Southwest State of Nigeria December 2015 to April 2016. CFR, IMS
12  2018 Non-neutralizing antibodies elicited by recombinant Lassa-Rabies vaccine are critical for protection against Lassa fever. coGPC, LASSARAB, LASV
13  2018 Persistence of Lassa Virus Associated With Severe Systemic Arteritis in Convalescing Guinea Pigs (Cavia porcellus). LASV
14  2018 The challenges of detecting and responding to a Lassa fever outbreak in an Ebola-affected setting. EVD, IDSR
15  2017 Lassa Virus Reverse Genetics. HF, LAV, MG, OW, RIB
16  2017 Management of a Lassa fever outbreak, Rhineland-Palatinate, Germany, 2016. VHF
17  2017 Understanding the cryptic nature of Lassa fever in West Africa. LASV
18  2016 Lassa Fever in Pregnancy: Report of 2 Cases Seen at the University College Hospital, Ibadan. ---
19  2016 Postexposure prophylaxis for Lassa fever: Experience from a recent outbreak in Nigeria. AEs, orPEP
20  2016 Vaccine platforms to control Lassa fever. LASV, RC
21  2015 Animal Model of Sensorineural Hearing Loss Associated with Lassa Virus Infection. LASV, SNHL
22  2015 Delayed inflammatory and cell death responses are associated with reduced pathogenicity in Lujo virus-infected cynomolgus macaques. LASV, LUJV, PBMC
23  2015 Development of a time-trend model for analyzing and predicting case-pattern of Lassa fever epidemics in Liberia, 2013-2017. ---
24  2015 Highly Pathogenic New World and Old World Human Arenaviruses Induce Distinct Interferon Responses in Human Cells. IFN, JUNV, LASV, MACV, NW, OW
25  2015 Lassa virus isolates from Mali and the Ivory Coast represent an emerging fifth lineage. LASV
26  2015 Lessons learnt from the management of a case of Lassa fever and follow-up of nosocomial primary contacts in Nigeria during Ebola virus disease outbreak in West Africa. ---
27  2015 Multiple circulating infections can mimic the early stages of viral hemorrhagic fevers and possible human exposure to filoviruses in Sierra Leone prior to the 2014 outbreak. EBOV, EVD, IgM, KGH, LASV, NLFI, WNV
28  2015 Novel mechanism of arenavirus-induced liver pathology. NHP, VHFs
29  2015 Using modelling to disentangle the relative contributions of zoonotic and anthroponotic transmission: the case of lassa fever. ---
30  2014 Constraints in the diagnosis and treatment of Lassa Fever and the effect on mortality in hospitalized children and women with obstetric conditions in a rural district hospital in Sierra Leone. ---
31  2014 Lassa fever in post-conflict sierra leone. CFRs, KGH, LASV
32  2014 Production of CXC and CC chemokines by human antigen-presenting cells in response to Lassa virus or closely related immunogenic viruses, and in cynomolgus monkeys with lassa fever. APC, DC, LASV, MOPV, MP, NP, rLASV
33  2014 The rubber plantation environment and Lassa fever epidemics in Liberia, 2008-2012: a spatial regression. LAC
34  2013 Containing a Lassa fever epidemic in a resource-limited setting: outbreak description and lessons learned from Abakaliki, Nigeria (January-March 2012). ---
35  2013 Mice lacking functional STAT1 are highly susceptible to lethal infection with Lassa virus. LASV
36  2013 The search for animal models for Lassa fever vaccine development. LASV
37  2012 Advanced vaccine candidates for Lassa fever. LASV
38  2012 Evaluation of Lassa virus vaccine immunogenicity in a CBA/J-ML29 mouse model. CMI, i.c, i.p, LASV
39  2012 Pathogenic Old World arenaviruses inhibit TLR2/Mal-dependent proinflammatory cytokines in vitro. ARM, Cl13, IL-6, LASV, LCMV, TLR2
40  2012 The sensitivity and specificity of Lassa virus IgM by ELISA as screening tool at early phase of Lassa fever infection. LAV, NP, RT-PCR
41  2012 Vaccine Platforms to Control Arenaviral Hemorrhagic Fevers. GP, HFs, JUNV, LASV, MACV, VLPV, YF
42  2011 Early-onset sensorineural hearing loss in Lassa fever. SNHL
43  2011 Emerging trends in Lassa fever: redefining the role of immunoglobulin M and inflammation in diagnosing acute infection. Ab-capture ELISA, Ag-capture ELISA, KGH, LASV, LFW, NF
44  2011 Human dendritic cells infected with the nonpathogenic Mopeia virus induce stronger T-cell responses than those infected with Lassa virus. APC, CTL, DC, LV, MV
45  2011 Lassa hemorrhagic fever in a late term pregnancy from northern Sierra Leone with a positive maternal outcome: case report. KGH LFW, LASV, LFI
46  2011 Yellow fever 17D-vectored vaccines expressing Lassa virus GP1 and GP2 glycoproteins provide protection against fatal disease in guinea pigs. LASV-GPC, YF
47  2010 T cell-dependence of Lassa fever pathogenesis. LASV, MHC-I
48  2008 New opportunities for field research on the pathogenesis and treatment of Lassa fever. MRU, MRU LFN, VHFs
49  2007 Development of recombinant nucleoprotein-based diagnostic systems for Lassa fever. Ag-capture, ELISA, LASV, LASV, rNP
50  2007 Fluctuation of abundance and Lassa virus prevalence in Mastomys natalensis in Guinea, West Africa. LASV, RT-PCR, TS
51  2001 Lassa fever in Guinea: II. Distribution and prevalence of Lassa virus infection in small mammals. ELISA, LV
52  1989 Clinical features of Lassa fever in Liberia. ---
53  1989 Pathogenesis of viral hemorrhagic fevers: Rift Valley fever and Lassa fever contrasted. DIC, RVF, VHF
54  1986 No evidence for increased risk of Lassa fever infection in hospital staff. ---
55  1985 Endemic Lassa fever in Liberia. IV. Selection of optimally effective plasma for treatment by passive immunization. IFA
56  1984 Endemic Lassa fever in Liberia. I. Clinical and epidemiological aspects at Curran Lutheran Hospital, Zorzor, Liberia. CLH
57  1984 Endemic Lassa fever in Liberia. II. Serological and virological findings in hospital patients. ---
58  1984 The use of Lassa fever convalescent plasma in Nigeria. LFCP
59  1978 Lassa fever (LF) and Marburg disease (MVD): occurrences, origins and diagnoses. ---
60  1977 A neutralization test survey for Lassa Fever activity in Lassa, Nigeria. ---